Precision oncology is revolutionizing cancer treatment by tailoring medical care based on the genetic makeup of a patient's tumor. However, significant disparities exist in the effectiveness and availability of these treatments among patients of different ancestries. This article delves into the
NEC Corporation and Biomy, Inc. have announced a groundbreaking partnership aimed at revolutionizing digital pathology through the integration of artificial intelligence (AI) and deep learning (DL). This collaboration, formalized in a recent Memorandum of Understanding (MoU), seeks to enhance
Groundbreaking research conducted by a collaborative team from Mount Sinai and Memorial Sloan Kettering Cancer Center has unveiled a novel mechanism by which monoamine neurotransmitters, specifically serotonin, dopamine, and histamine, regulate brain physiology and behavior. This research
The field of drug discovery has long been challenged by the concept of "undruggable" targets—proteins and pathways that are crucial in disease processes but difficult to target with traditional small molecule drugs. One particularly challenging target is β-catenin, a key player in the Wnt/β-catenin
Imagine a world where cancer patients could receive personalized treatment precisely tailored to their unique biological makeup, drastically improving their chances of success. This once-idealistic vision is now becoming a reality with the advent of SCORPIO, an innovative AI-driven tool developed
Glioblastoma, an aggressive and often fatal form of brain cancer, has long posed a formidable challenge to medical professionals. With an average lifespan of 12 to 15 months post-diagnosis and a mere 5% survival rate five years after diagnosis, the need for innovative treatments has never been more
